Stockscreener 앱 받기
39.60
5.92%
-2.49
시간 외 거래:
39.60
Merus N V 주식(MRUS)의 최신 뉴스
How To Trade (MRUS) - news.stocktradersdaily.com
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading Biotech Merus Showcases Next-Gen Antibody Technologies at Major Healthcare Conference - Stock Titan
Merus (NASDAQ:MRUS) Shares Purchased by Teacher Retirement System of Texas - Defense World
Guggenheim Reiterates “Buy” Rating for Merus (NASDAQ:MRUS) - Defense World
Swiss National Bank Purchases 8,300 Shares of Merus (NASDAQ:MRUS) - Defense World
Merus VP controller Shuman sells $193,990 in common shares By Investing.com - Investing.com Australia
Merus VP controller Shuman sells $193,990 in common shares - Investing.com
Bank of New York Mellon Corp Sells 1,248 Shares of Merus (NASDAQ:MRUS) - Defense World
US Bancorp DE Lowers Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus (NASDAQ:MRUS) Given “Buy” Rating at Guggenheim - Defense World
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Given New $70.00 Price Target at Bank of America - Defense World
Why Merus Shares Are Facing Pressure Today - TipRanks
Merus (NASDAQ:MRUS) Short Interest Down 13.5% in February - Defense World
Stifel maintains Buy on Merus stock with $93 target By Investing.com - Investing.com Australia
Stifel maintains Buy on Merus stock with $93 target - Investing.com
Merus N.V. Reports 2024 Earnings and Clinical Progress - TipRanks
Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025 - Simply Wall St
Merus (NASDAQ:MRUS) Receives “Buy” Rating from HC Wainwright - Defense World
Merus stock holds Buy rating and $85 target from H.C. Wainwright - Investing.com India
Merus stock holds Buy rating and $85 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Merus’ (MRUS) Outperform Rating Reiterated at William Blair - Defense World
Needham & Company LLC Cuts Merus (NASDAQ:MRUS) Price Target to $83.00 - Defense World
Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - Simply Wall St
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS) - Yahoo Canada Finance
Merus (NASDAQ:MRUS) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPS - MarketBeat
BMO Capital lifts Merus stock target to $96, maintains Outperform By Investing.com - Investing.com South Africa
BMO Capital lifts Merus stock target to $96, maintains Outperform - Investing.com
Merus Shares Soar Amid Breakthrough Therapy Hopes - TipRanks
Merus NV reports results for the quarter ended December 31Earnings Summary - TradingView
Merus N.V. Updates on Petosemtamab Trials and Financial Outlook for 2025 and Beyond - Nasdaq
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewswire
Merus Secures FDA Approval for Cancer Drug With $724M War Chest to Fund Operations Through 2028 - StockTitan
Merus N.V. SEC 10-K Report - TradingView
Merus N.V. to Host Earnings Call - ACCESS Newswire
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
State of New Jersey Common Pension Fund D Buys 10,842 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Oncology Innovator Merus Schedules Two Major Investor Presentations - StockTitan
Merus (MRUS) to Release Quarterly Earnings on Wednesday - MarketBeat
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus Stock Soars on Cancer Treatment Breakthrough - TipRanks
3.89%
0.13%
자본화:
|
볼륨(24시간):